Drug
Epetraborole clinical trials
Also written GSK2251052.
- studies test it
- 13
- open now
- 2
- in phase 3
- 1
- first study started
- 2009
Keep track of what changes. Save the epetraborole studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2011 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 5 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 5
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
GlaxoSmithKline (6) · AN2 Therapeutics, Inc (5) · Pfizer (1) · Kevin Winthrop (1)
Studies
Open first, then newest update. How each study uses epetraborole is read from its arms, and is right about nine times in ten.
Testing it · 13
- Phase 2 Study of Oral Epetraborole in Adults With Polycythemia VeraNot yet recruitingPhase 2AN2 Therapeutics, IncNCT07891533Written as Epetraborole
- Epetraborole in Patients With Mycobacterium Abscessus Lung DiseaseRecruitingPhase 2Kevin WinthropNCT07301320Written as Epetraborole
- Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseTerminatedPhase 2/3AN2 Therapeutics, IncNCT05327803Written as Epetraborole
- Phase 1 Study of Epetraborole TabletsCompletedPhase 1AN2 Therapeutics, IncNCT04892641Written as Epetraborole
- A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult SubjectsCompletedPhase 1AN2 Therapeutics, IncNCT05995444Written as Epetraborole
- A Study of Epetraborole Tablets in Subjects With Degrees of Renal FunctionCompletedPhase 1AN2 Therapeutics, IncNCT05283746Written as Epetraborole
- Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial InfectionsCompletedPhase 1PfizerNCT01015014Written as AN3365
- GSK2251052 in the Treatment of Complicated Intra-abdominal InfectionsTerminatedPhase 2GlaxoSmithKlineNCT01381562Written as Drug: GSK2251052
- GSK2251052 in Complicated Urinary Tract InfectionTerminatedPhase 2GlaxoSmithKlineNCT01381549Written as GSK2251052
- An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult SubjectsCompletedPhase 1GlaxoSmithKlineNCT01267968Written as GSK2251052
- A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult SubjectsCompletedPhase 1GlaxoSmithKlineNCT01262885Written as GSK2251052
- A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase StudyTerminatedPhase 1GlaxoSmithKlineNCT01702350Written as GSK2251052
- A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy VolunteersTerminatedPhase 1GlaxoSmithKlineNCT01495065Written as GSK2251052 750 mg
Codes
What other systems call epetraborole · ClinicalTrials.gg INT006362
- UNII (FDA) 6MC93Z2DF9EPETRABOROLEConfirmed FDA, Wikidata
- Wikidata Q27265149epetraboroleConfirmed FDA, Wikidata
- NCI Thesaurus C166950EpetraboroleOne source FDA
- DrugBank DB11744One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6MC93Z2DF9 | EPETRABOROLE | Confirmed FDA, Wikidata |
| Wikidata | Q27265149 | epetraborole | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166950 | Epetraborole | One source FDA |
| DrugBank | DB11744 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.